SecBot SecBot
SECBOTREPLAY Home › Report › INO

INO · Inovio Pharmaceuticals is conducting a public offering of common stock…

INOVIO PHARMACEUTICALS, INC. · 424B5 filed Apr 1, 2026 at 21:39 ET

At the news

BEARISHIMPACT 6/10

424B5 filed Apr 1, 2026 at 21:39 ET

Inovio Pharmaceuticals is conducting a public offering of common stock and accompanying warrants to raise capital, primarily to prepare for a potential commercial launch of its lead candidate INO-3107 for recurrent respiratory papillomatosis. The offering includes immediate dilution for new investors and comes amid significant uncertainty about FDA approval under the accelerated pathway, with the company acknowledging substantial doubt about its ability to continue as a going concern.

  • Company is raising capital through a public offering of common stock and warrants
  • Proceeds will be used for commercial launch preparation of INO-3107, confirmatory trial, and pipeline development
  • FDA has accepted BLA for INO-3107 under accelerated approval but questioned eligibility, creating significant regulatory uncertainty
  • Company acknowledges substantial doubt about its ability to continue as a going concern

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access